Replies to post #84820 on Cytodyn Inc (CYDY)

[Borel Fields]

Given that science by press release is now standard, does that mean we'll put out a press release the night the s/c trial hits 28 days?

[clambottler]

VERY VERY GREAT - for CYDY 1/8 1/25 dexamethasone

“The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become standard of care in these patients. "

--- So this small a result is now an announced Standard of Care ---

CYDY JUST HAS TO SAVE 2 OF 8 AND THEY -- DOUBLE -- THE BENEFICIAL EFFECT OF STANDARD OF CARE -----

Researchers estimated that the drug would prevent one death for every eight patients treated while on breathing machines and one for every 25 patients on extra oxygen alone.

First drug proves able to improve survival from COVID-19
By MARILYNN MARCHIONE
an hour ago


The World Health Organization advises against using steroids earlier in the course of illness because they can slow the time until patients clear the virus.


The drug was given either orally or through an IV. After 28 days, it had reduced deaths by 35% in patients who needed treatment with breathing machines and by 20% in those only needing supplemental oxygen. It did not appear to help less ill patients.

https://apnews.com/89d963958b042cc921e64ab3eff5a74d

[Chuckles759]

Was this an oversight by leaving the following sentence out of your quote?

Based on these results, 1 death would be prevented by treatment of around 8 ventilated patients or around 25 patients requiring oxygen alone.

Pretty critical, distilled information to quickly assess the efficacy of the drug compared to others - especially leronlimab.

[Monroe1]

Big pharma is running scared of CytoDyn. Hail Mary's thrown into a strong headwind fail to meet their target. Fake News junk science and rearranging of data doesn't work like it once did. Inquiring minds see the false narrative plain as day. The average observer in new medicine related stocks unfortunately is a bit more sophisticated than the target audience of your typical news outlet. Let's see how they spin Leronlimab in a few weeks.